Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 8, 2012 - Issue 5
Submit an article Journal homepage
235
Views
9
CrossRef citations to date
0
Altmetric
Drug Profile

Rituximab: emerging treatment strategies of immune-mediated glomerular disease

Andrea G Kattah Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA
&
Fernando C Fervenza Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA. [email protected]
Pages 413-421 | Published online: 10 Jan 2014

References

  • Finkielman JD, Lee AS, Hummel AM et al.; WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am. J. Med. 120(7), 643.e9–14 (2007).
  • Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. 17(5), 1235–1242 (2006).
  • Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20(5), 517–527 (2004).
  • Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361(1), 11–21 (2009).
  • Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J. Nephrol. 21(6), 813–825 (2008).
  • Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2(9), 764–766 (2001).
  • Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48(6), 1484–1492 (2003).
  • Genovese MC, Kaine JL, Lowenstein MB et al.; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(9), 2652–2661 (2008).
  • Rigby W, Tony HP, Oelke K et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group Phase III trial. Arthritis Rheum. 64(2), 350–359 (2012).
  • Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr. Opin. Rheumatol. 23(3), 245–251 (2011).
  • Kappos L, Li D, Calabresi PA et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a Phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805), 1779–1787 (2011).
  • Østergaard M, Baslund B, Rigby W et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, Phase I/II study. Arthritis Rheum. 62(8), 2227–2238 (2010).
  • Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48(8), 2146–2154 (2003).
  • Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 122(1), 62–74 (2007).
  • Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173(2), 180–187 (2006).
  • Fervenza FC. Rituximab in ANCA-associated vasculitis: fad or fact? Nephron. Clin. Pract. 118(2), c182–c188; discussion c188 (2011).
  • Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 29(4), 388–397 (2006).
  • Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95(12), 3900–3908 (2000).
  • Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20(4), 444–449 (2008).
  • Stone JH, Merkel PA, Spiera R et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363(3), 221–232 (2010).
  • Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73(1), 117–125 (2008).
  • Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg–Strauss syndrome with renal involvement. Nephrol. Dial. Transplant. 26(9), 2865–2871 (2011).
  • Fervenza FC, Abraham RS, Erickson SB et al.; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 5(12), 2188–2198 (2010).
  • Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90(6), 2188–2195 (1997).
  • Clayton AR, Savage CO. Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin. Exp. Immunol. 132(1), 174–179 (2003).
  • Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52(1), 262–268 (2005).
  • Lovric S, Erdbruegger U, Kümpers P et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol. Dial. Transplant. 24(1), 179–185 (2009).
  • Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60(7), 2156–2168 (2009).
  • Jones RB, Tervaert JW, Hauser T et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363(3), 211–220 (2010).
  • Specks U, Stone JH; for the RAVE-ITN Research Group. Long-term efficacy and safety results of the RAVE trial. Clin. Exp. Immunol. 164, 65 (2011).
  • Noth I, Strek ME, Leff AR. Churg–Strauss syndrome. Lancet 361(9357), 587–594 (2003).
  • Keogh KA, Specks U. Churg–Strauss syndrome. Semin. Respir. Crit. Care Med. 27(2), 148–157 (2006).
  • Dønvik KK, Omdal R. Churg–Strauss syndrome successfully treated with rituximab. Rheumatol. Int. 31(1), 89–91 (2011).
  • Pepper RJ, Fabre MA, Pavesio C et al. Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 47(7), 1104–1105 (2008).
  • Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg–Strauss syndrome. Ann. Rheum. Dis. 65(8), 1116–1117 (2006).
  • Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg–Strauss syndrome. Ann. Rheum. Dis. 65(4), 557–559 (2006).
  • Cattran DC. Membranous nephropathy: quo vadis? Kidney Int. 61(1), 349–350 (2002).
  • Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 360(9337), 923–924 (2002).
  • Cravedi P, Noris M, Remuzzi G. Report of the first World Transplant Congress. Clin. J. Am. Soc. Nephrol. 2(2), 393–400 (2007).
  • Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 14(7), 1851–1857 (2003).
  • McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825–2833 (1998).
  • Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54(8), 2377–2386 (2006).
  • Ruggenenti P, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 1(4), 738–748 (2006).
  • Herishanu Y. Rituximab-induced serum sickness. Am. J. Hematol. 70(4), 329 (2002).
  • Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354, 1932–1939 (1999).
  • Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580–2589 (2004).
  • Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135–3143 (2000).
  • Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 87(2), 189–195 (2002).
  • Beck LH Jr, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22(8), 1543–1550 (2011).
  • Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol. 4(4), 734–744 (2009).
  • Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 31(4), 341–348 (2011).
  • Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 64(3), 835–842 (2012).
  • De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64(3), 843–853 (2012).
  • Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45(7), 842–846 (2006).
  • Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC. Rituximab therapy for type I membranoproliferative glomerulonephritis. Clin. Nephrol. 77(4), 290–295 (2012).
  • Cameron JS. Lupus nephritis. J. Am. Soc. Nephrol. 10(2), 413–424 (1999).
  • Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353(21), 2219–2228 (2005).
  • Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314(10), 614–619 (1986).
  • Boumpas DT, Austin HA 3rd, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340(8822), 741–745 (1992).
  • Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52(2), 501–513 (2005).
  • Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56(4), 1263–1272 (2007).
  • Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46(10), 2673–2677 (2002).
  • Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54(9), 2970–2982 (2006).
  • Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1), 222–233 (2010).
  • Rovin BH, Furie R, Latinis K et al.; for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab (LUNAR) Study. Arthitis Rheum. 64(4), 1215–1226 (2012).
  • François H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am. J. Kidney Dis. 49(1), 158–161 (2007).
  • Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol. Dial. Transplant. 22(7), 2100–2102 (2007).
  • Fujinaga S, Hirano D, Nishizaki N et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr. Nephrol. 25(3), 539–544 (2010).
  • Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. Nephron. Clin. Pract. 120(2), c79–c85 (2012).
  • Sawara Y, Itabashi M, Kojima C et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin. Nephrol. 72(1), 69–72 (2009).
  • Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol. Dial. Transplant. 23(1), 377–380 (2008).
  • Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin. Nephrol. 76(2), 151–158 (2011).
  • Fernandez-Fresnedo G, Segarra A, González E et al.; Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 4(8), 1317–1323 (2009).
  • Prytula A, Iijima K, Kamei K et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 25(3), 461–468 (2010).
  • Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin. J. Am. Soc. Nephrol. 5(12), 2363–2372 (2010).
  • Gottenberg JE, Guillevin L, Lambotte O et al.; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64(6), 913–920 (2005).
  • Larsen JL, Jacobsen S. Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. Rheumatol. Int. doi:10.1007/s00296-011-2208-0 (2011) (Epub ahead of print).
  • Choy DS, Weiss A, Lin PT. Progressive multifocal leukoencephalopathy following treatment for Wegener’s granulomatosis. JAMA 268(5), 600–601 (1992).
  • Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56(7), 2116–2128 (2007).
  • Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J. Infect. Chemother. 11(4), 189–191 (2005).
  • Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br. J. Dermatol. 155(5), 1053–1056 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.